GATC Health Corp, a privately-held biotech company using artificial intelligence, genomics and advanced biological data to revolutionize drug discovery and disease prediction, is pleased to announce that it has been invited to present at the Emerging Growth Conference on February 16, 2022 at 1:00pm EST.
This live, 30 minute interactive online event, will allow existing shareholders, prospective shareholders, and the investment community to interact with the Company’s Chief Operating Officer, Mr. Tyrone Lam, and Chief Marketing Officer, Ms. Preetaman Wadhwa, in real-time.
GATC Health will present its leading-edge solution to create safer, more effective therapeutics in record time using its Advanced AI platform. The company may subsequently open the floor for questions. Questions not answered during the live event may be addressed by the company after its presentation through email.
Please register HERE to ensure you can attend the conference and receive any released updates. If attendees cannot join the event live on the day of the conference, an archived webcast will also be made availalble on EmergingGrowth.com, and we will also release a link to that after the event.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services, and other major announcements to the investment community from the convenience of their office, in a time-efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, investment advisors, and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About GATC Health
GATC Health Corp is a pioneering biotechnology company using whole-genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patent-pending AI platform reduces risk, time and costs for life science companies by digitally reproducing the human body to find non-obvious answers to biology’s most complex questions. GATC Health is accelerating healthcare’s transition to predictive, individualized medicine.
The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.